other material
confidence high
sentiment positive
materiality 0.65
Dogwood provides HALT-CINP trial update; $12.5M raised, SP16 IND filed
Dogwood Therapeutics, Inc.
- 145 patients recruited in Halneuron Phase 2b HALT-CINP study; final data expected fall 2026.
- Raised $12.5M in Q1 2026; combined with year-end cash extends runway through data release.
- Filed IND for SP16 IV (chemo-induced neuropathy); Phase 1b fully funded by NCI grant.
- Advanced synthetic Halneuron formulation for Phase 3; aims to cut costs and boost yields.